TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06132217: A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 168 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06132217 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06132217 Rescue Dossier →